EUVIMEDEUVIMED entdecken
Open Access

Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters

Rafael Enrique Sanchez-Pupo, John Joseph Kelly, Nourhan Shalaby, Ying Xia, Francisco Manuel Martinez-Santiesteban, Jasmine Lau, Ivy Elizabeth Verriet, Matthew Stefan Fox, Justin Wesley Hicks, Jonathan Dale Thiessen, John Andrew Ronald

Theranostics · 01.01.2026 · 16 (7) · 3227-3245

DOI: 10.7150/thno.119013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 01.01.2026. Verfasst von Rafael Enrique Sanchez-Pupo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Robarts Research Institute, University of Western Ontario, London, ON, Canada. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Chimeric antigen receptor (CAR) T cell therapies have shown remarkable success in treating hematological cancers and are increasingly demonstrating potential for solid tumors. CRISPR-based genome editing offers a promising approach to enhance the potency and safety of CAR-T cells. However, several challenges persist, including inefficient tumor homing and treatment-related toxicities in normal tissues, which continue to hinder widespread adoption. Advanced imaging technologies, including bioluminescence imaging (BLI) and positron emission tomography (PET), provide real-time insights into CAR-T cell distribution and activity in vivo, both in preclinical models and in patients. Here, we developed Trackable Reporter Adaptable CRISPR-Edited CAR (tRACE-CAR) T cells, a modular system for site-specific integration of CARs and imaging reporters.

Methods

The luciferase reporter AkaLuciferase (AkaLuc) or the human sodium iodide symporter (NIS) were cloned downstream of the CAR in adeno-associated virus (AAV) donors for BLI or PET tracking, respectively. CARs with imaging reporters were knocked into the TRAC locus of primary human T cells via CRISPR editing and AAV transduction. Editing efficiency was evaluated by flow cytometry and junction PCR. In vitro cytotoxicity was assessed by BLI using firefly luciferase (Fluc)-expressing cancer cells co-cultured with CAR-T cells at varying effector-to-target ratios. In vivo, BLI and PET imaging assessed CAR-AkaLuc and CAR-NIS T cell expansion and trafficking in Nod-SCID-gamma mice bearing xenograft tumors.

Results

T cell receptor (TCR) knockout efficiency exceeded 85%, with CAR expression observed in 70–80% of cells, depending on the reporter used. Reporter-engineered CAR-T cells retained functionality in vitro and exhibited significant cytotoxicity against target cancer cells, outperforming naïve T cells. In vivo, AkaLuc BLI and 18 F-tetrafluoroborate PET enabled non-invasive tracking of viable CAR-T cells. Notably, the route of administration (intravenous, peritumoral, or intraperitoneal) significantly influenced the distribution of CAR-T cells and their therapeutic effectiveness. Conclusion tRACE-CAR enabled precise optical and PET tracking of CAR-T cells in models of B cell leukemia and ovarian cancer, allowing dynamic, non-invasive monitoring of cell distribution in both tumors and off-target tissues. This imaging platform could lead to more personalized, effective CRISPR-edited CAR cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesGene EditingHumansAnimalsMiceFemaleGenes, ReporterCRISPR-Cas SystemsOptical Imaging

Stichwörter der Autor:innen

CAR-TCRISPR-based genome editingPETcell trackingimmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Robarts Research Institute, University of Western Ontario, London, ON, Canada.
  • Dept. of Medical Biophysics, University of Western Ontario, London, ON, Canada.
  • Lawson Health Research Institute, London, ON, Canada.
  • Dept. of Physics and Astronomy, University of Western Ontario, London, ON, Canada.
  • Dept. of Medical Physics, CancerCare Manitoba, Winnipeg, MB, Canada.
  • Dept. of Radiology, University of Manitoba, Winnipeg, MB, Canada.

Zitieren

APA

Sanchez-Pupo, R. E., Kelly, J. J., Shalaby, N., Xia, Y., Martinez-Santiesteban, F. M., Lau, J., Verriet, I. E., Fox, M. S., Hicks, J. W., Thiessen, J. D., & Ronald, J. A. (2026). Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters. Theranostics, 16(7), 3227-3245. https://doi.org/10.7150/thno.119013

Vancouver

Sanchez-Pupo RE, Kelly JJ, Shalaby N, Xia Y, Martinez-Santiesteban FM, Lau J, et al. Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters. Theranostics. 2026;16(7):3227-3245. doi:10.7150/thno.119013

BibTeX
@article{SanchezPupo2026,
  author = {Sanchez-Pupo, Rafael Enrique and Kelly, John Joseph and Shalaby, Nourhan and Xia, Ying and Martinez-Santiesteban, Francisco Manuel and Lau, Jasmine and Verriet, Ivy Elizabeth and Fox, Matthew Stefan and Hicks, Justin Wesley and Thiessen, Jonathan Dale and Ronald, John Andrew},
  title = {Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters},
  journal = {Theranostics},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {3227--3245},
  doi = {10.7150/thno.119013}
}
Kostenlos starten →